Réalisées par des traducteurs professionnels, des entreprises, des pages web ou traductions disponibles gratuitement.
this will then release an egg, after an injection of the hormone “human chorionic gonadotropin (hcg)”.
denne vil dernæst frigive et æg, efter en injektion af hormonet “humant choriongonadotropin (hcg)”.
ohss may be caused by administration of human chorionic gonadotropin (hcg) and by pregnancy (endogenous hcg).
ohss kan forårsages af administration af human chorion gonadotropin (hcg) og af graviditet (endogen hcg).
treatment with (rec)fsh is then stopped and the eggs are matured by giving hcg (human chorionic gonadotropin).
herefter stoppes behandlingen med (rec)fsh, og æggene modnes ved at give hcg (humant choriongonadotropin).
it is made by a cell that has received a gene (dna), which makes it able to produce human chorionic gonadotropin.
det produceres af en celle, der har fået indsat et gen (dna), som sætter den i stand til at producere humant choriogonadotropin.
acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.
stimulation af spermatogenesen hos mænd, som har medfødt eller erhvervet hypogonadotrop hypogonadisme.
· gonal-f is used in combination with another medicine, human chorionic gonadotrophin
· gonal-f bruges i kombination med en anden medicin, human chorionic gonadotropin (hcg) ,
in women, chorionic gonadotropin acts as a surrogate luteinising hormone surge that triggers ovulation.
hos kvinder har choriongonadotropin samme effekt som en pludselig luteiniserende hormon-stigning der fremkalder ovulation.
administration of (rec)fsh on the day of human chorionic gonadotropin (hcg) administration can be omitted, depending on the ovarian response.
afhængigt af ovarielt respons, kan administration af (rec)fsh undlades på dagen for administration af humant choriongonadotropin. (hcg).
bemfola treatment seldom causes severe ohss unless the medicine that is used for final follicular maturation (containing human chorionic gonadotropin, hcg) is administered.
bemfola-behandling fører sjældent til alvorlig ohss, medmindre medicinen, man anvender for at inducere afsluttende follikelmodning (indeholdende humant choriongonadotropin – hcg), er indgivet.
gonal-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotropin (hcg) therapy.
gonal-f er indiceret til stimulation af spermatogenesen hos mænd, som har medfødt eller erhvervet hypogonadotrop hypogonadisme i kombination med behandling med humant choriongonadotropin (hcg).
gonal-f treatment seldom causes severe ohss unless the medicine that is used for final follicular maturation (containing human chorionic gonadotropin, hcg) is administered.
gonal-f-behandling fører sjældent til alvorlig ohss, medmindre medicinen man anvender for at inducere afsluttende follikelmodning (indeholdende humant choriongonadotropin - hcg), er indgivet.
it is followed by treatment with a single dose of human chorionic gonadotropin (hcg), which leads to the release of an egg from the follicle (ovulation).
efter behandlingen gives en enkelt dosis af human choriongonadotropin (hcg), som fører til frigivelsen af et æg fra folliklen (ægløsning).
a few days later, a hormone such as hcg (human chorionic gonadotropin) is given to trigger ovulation, and the eggs are then harvested and used in techniques such as in-vitro fertilisation.
nogle få dage senere gives et hormon som for eksempel hcg (human chorionic gonadotropin) til at fremkalde ægløsning, og æggene udtages derefter og anvendes til teknikker såsom in vitro - befrugtning.
a negative, sensitive, pregnancy test (e.g. serum beta-human chorionic gonadotropin, beta-hcg) should be obtained within one week prior to bexarotene therapy.
en negativ, følsom, graviditetsprøve (f.eks. serum-beta-humant choriongonadotropin, beta-hcg) bør foretages inden for en uge inden påbegyndelsen af bexaroten- terapi.